Lupin Healthcare has announced the launch of the Luforbec beclometasone/formoterol MDI in the UK. The generic version of Chiesi’s Fostair MDI was approved by the MHRA for the treatment of asthma and COPD in June 2021. According to Lupin, the Luforbec inhaler will be manufactured at the company's facilities in the US and India. The company cited UK prescribing data … [Read more...] about Lupin launches Luforbec beclometasone/formoterol MDI in the UK
Business
Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx's SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19. The project is supported by Swiss life sciences investment company ADYA Consulting. According to the … [Read more...] about Crystec and SignalRx partner on development of inhaled P13K-BRD4 inhibitor
Cellics partners with HCmed on delivery of inhaled nanosponges
Nebulizer maker HCmed Innovations and Cellics Therapeutics have agreed to collaborate on inhaled delivery of cellular nanosponges as antibacterial and anti-inflammatory therapies. Cellics is currently developing nanosponges based on red blood cells and macrophages, and the company expects to advance its CTI-005 RBC nanosponge into clinical development for the … [Read more...] about Cellics partners with HCmed on delivery of inhaled nanosponges
Aptar Pharma gets option to acquire Pharmaxis’s Orbital DPI
Aptar Pharma will have 12 months to decide whether to exercise an exclusive option to acquire worldwide rights to Pharmaxis's high payload Orbital dry powder inhaler under a new agreement, the company said. The Orbital DPI, which can deliver up to 400 mg of powder in divided doses, was designed for delivery of Pharmaxis's Bronchitol inhaled mannitol, and Pharmaxis … [Read more...] about Aptar Pharma gets option to acquire Pharmaxis’s Orbital DPI
Philip Morris acquires Asprihale developer OtiTopic
Philip Morris International (PMI) has acquired inhaled drug developer OtiTopic, as "part of PMI’s strategic plan to leverage its expertise, scientific know-how, and capabilities in inhalation to grow a pipeline of inhaled therapeutics and respiratory drug delivery Beyond Nicotine," the company said. PMI recently announced a £1 billion offer for inhalation CDMO … [Read more...] about Philip Morris acquires Asprihale developer OtiTopic
Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye
Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma's OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes a $17.5 million upfront payment and up to $204.8 million in milestone payments and royalties. Earlier this year, Ji Xing acquired … [Read more...] about Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye
Insmed launches Arikayce in Japan, advances TPIP into Phase 2 trials
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry of Health, Labour and Welfare approved Arikayce for that indication in March 2021. The company also … [Read more...] about Insmed launches Arikayce in Japan, advances TPIP into Phase 2 trials
NRx, MannKind partner on possible Zyesami aviptadil DPI
MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind's Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its facility in Danbury, CT, USA. TFF Pharmaceuticals had previously announced that it was conducting a feasibility study to … [Read more...] about NRx, MannKind partner on possible Zyesami aviptadil DPI
Relief Therapeutics acquires AdVita Lifescience, gets orphan drug designation for inhaled aviptadil for sarcoidosis
According to Relief Therapeutics, the FDA has granted orphan drug designation for RLF-100 inhaled aviptadil for the treatment of sarcoidosis; RLF-100 is currently in Phase 2 development for that indication. Relief also recently acquired German company AdVita Lifescience, which has been developing inhaled aviptadil for human and veterinary use, with Relief citing the … [Read more...] about Relief Therapeutics acquires AdVita Lifescience, gets orphan drug designation for inhaled aviptadil for sarcoidosis
Sanofi to acquire Translate Bio
Sanofi has agreed to pay approximately $3.2 billion for Translate Bio, which is developing inhaled mRNA therapies for cystic fibrosis, primary ciliary dyskinesia, and pulmonary arterial hypertension in addition to a number of intramuscular mRNA vaccines, including vaccines against COVID-19 and influenza. Sanofi is currently partnered with Translate on the … [Read more...] about Sanofi to acquire Translate Bio